Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44’s initial dystrophin increase was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results